|
KMID : 0378019890320060087
|
|
New Medical Journal
1989 Volume.32 No. 6 p.87 ~ p.90
|
|
|
Clinical Effects of Miocamycin(9,3"-Diacetylmidecamycin) on Respiratory Tract Infection in Children
|
|
|
|
|
Abstract
|
|
|
|
Miocamycin(9,3"-Diacetylmidecamycin), so-called "MOM", a macrolide antibiotic developed in Meiji Seika Pharmaceutical Company, Japan, is known to have excellent effect on the most of the Gram-positive cocci along with some of the Gram-negative organisms and myciplasmas. We have administered this oral antibiotic to the pediatric patients with respiratory tract infections, such as pneumonia, acute bronchitis, and acute pharyngitis, and evaluated clinical efficacy and adverse effects. Out of 51 patients 18 showed significant improvement ´thin 48 hours, and additional 20 within 72 hours of "MOM" therapy, i.e. total of 74.5% res.,Ended well within Ways. Gram-positive cocci grew in most of the throat culture specimen; . d 3 patients revealed antibodies to mycoplasma. There were few adverse effects observed One may conclude that Miocamycin is a safe and effective antibiotic for use in respiratory tract infections in pediatric patients,
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|